#China #Shanghai #ZEISS #Myopia #PT LUNANA

ZEISS Expands Myopia Solutions in China

In a significant advancement for the treatment of myopia, ZEISS Medical Technology recently showcased its next-generation phakic intraocular lens, the PT LUNANA®, at the 9th China International Import Expo (CIIE) in Shanghai. This innovative solution aims to combat the alarming rise of myopia within China, which has become a pressing public health issue in the region.

The Myopia Crisis in China

Current research indicates that approximately 600 million individuals in China suffer from myopia, with a staggering 67.2% of those aged between 15 to 19 afflicted by the condition. Additionally, around 9.5% of this demographic experiences high myopia, a serious visual impairment that can lead to further complications. The National Medical Products Administration (NMPA) of China has officially approved the PT LUNANA lens, marking a crucial milestone in ZEISS's strategy to relieve this public health challenge.

Innovative Design and Features

The PT LUNANA phakic IOL stands out for its cutting-edge aspheric optical design, which aims to provide improved visual quality and correction tailored to the needs of individual patients. Made from AQUAFLEX® hydrophilic polymer material, it promotes enhanced flexibility, clarity, and stability in diverse visual conditions. The lens is designed to cater to a range of myopia levels, presenting a viable option for patients with thin corneas or severe myopia who may not be suitable candidates for laser correction.

This innovative lens is set to be manufactured locally by Wuxi Carl Zeiss Vision Pro Medical Technology Co., Ltd, a collaborative endeavor between ZEISS and local partners in China. This localized production not only underscores ZEISS's commitment to innovation in the region but also speaks volumes about the company's dedication to addressing both local needs and global challenges.

Commitment to Personalized Care

As the prevalence of myopia continues to escalate in China, ZEISS executives emphasize the need for individualized patient care. Andreas Völker, Head of the Ophthalmology Strategic Business Unit at ZEISS Medical Technology, expressed that the PT LUNANA lens represents more than just a product – it's a reflection of ZEISS's commitment to innovation and personalized treatment pathways that enhance vision correction options.

The lens comes in a variety of sizes and power options, ensuring that healthcare providers can offer customized solutions for patients, further validating ZEISS’s approach to individualized fitting. Professor Wang Xiaoying, Chief Physician at the Eye and ENT Hospital of Fudan University in Shanghai, highlights that the increased variety of lens sizes available with the PT LUNANA will empower physicians to make tailored decisions that align with their patients’ unique needs.

Looking Forward: Commercial Availability

ZEISS aims to launch these groundbreaking phakic IOLs in China by 2027, subsequently extending their reach to the global market. The approval and upcoming commercialization of the PT LUNANA highlight ZEISS's proactive approach to enhancing the availability of effective myopia treatment options. As healthcare systems react to the growing demands stemming from the myopia epidemic, this launch represents a leap forward in providing innovative solutions.

In tackling the myopia crisis, ZEISS is not only focused on expanding their product portfolio but also aims to enhance the standard of vision health through collaborative efforts with local partners. Martin Fischer, President and CEO of ZEISS Greater China, reflected on this synergy, which combines groundbreaking optical technology with a localized innovation strategy to yield higher quality healthcare solutions.

The introduction of the PT LUNANA lens is a pivotal step in addressing the ongoing myopia epidemic in China, offering hope for millions in need of effective vision correction solutions. As ZEISS prepares for its local manufacturing and eventual global rollout, the company's commitment to improving eye health remains steadfast and inspiring.